Bioactive xanthones with effect on P-glycoprotein and prediction of intestinal absorption

Medicinal Chemistry Research

Volumn 22, Issue 5, 2013, Pages 2115-2123

  Sousa, Emília ^a   Palmeira, Andreia ^a   Cordeiro, Ana Sara ^a   Sarmento, Bruno ^a   Ferreira, Domingos ^a   Lima, Raquel T ^a   Helena Vasconcelos, M ^a   Pinto, Madalena ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Antitumor; P glycoprotein; Permeability; Xanthones

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; PYRANOXANTHONE; RHODAMINE; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE; XANTHONOLIGNOID;

ARTICLE; CANCER GROWTH; CANCER THERAPY; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG PENETRATION; ENZYMATIC ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; LEUKEMIA CELL; LUMINESCENCE; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN EXPRESSION;

EID: 84879681792     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0203-y     Document Type: Article

References (38)

1. Balimane PV, Han YH, Chong S (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 8(1):E1-E13. doi: 10.1208/aapsj080101
2. Boumendjel A, Di Pietro A, Dumontet C, Barron D (2002) Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22(5):512-529. doi: 10.1002/med.10015
3. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G (1998) Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 6(4):317-324. doi: S0928098797100197 [pii]
4. Eddershaw PJ, Beresford AP, Bayliss MK (2000) ADME/PK as part of a rational approach to drug discovery. Drug Discov Today 5(9):409-414. doi: S1359-6446(00)01540-3 [pii]
5. Ford JM (1996) Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A(6):991-1001
6. Goda K, Bacso Z, Szabo G (2009) Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets 9(3):281-297
7. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1):48-58. doi: 10.1038/nrc706
8. He Y, Zeng S (2005) Transport characteristics of rutin deca (H-) sulfonate sodium across Caco-2 cell monolayers. J Pharm Pharmacol 57(10):1297-1303. doi: 10.1211/jpp.57.10.0008
9. Hennessy M, Spiers JP (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55(1):1-15. doi: 10.1016/j.phrs.2006. 10.007 S1043-6618(06)00189-7 [pii]
10. ICH harmonised tripartite guideline (2005) Validation of analytical procedures: text and methodology Q2(R1). International Conference on Harmonization. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Quality/Q2-R1/Step4/Q2-R1--Guideline.pdf. Accessed 27 August 2012
11. Johnson D (1999) The discovery-development interface has become the new interfacial phenomenon. Drug Discov Today 4(12):535-536. doi: S1359-6446(99)01423-3 [pii]
12. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1):152-162. doi: 0005-2736(76)90160-7 [pii]
13. Kostakis IK, Tenta R, Pouli N, Marakos P, Skaltsounis A-L, Pratsinis H, Kletsas D (2005) Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells. Bioorg Med Chem Lett 15(22):5057-5060
14. Levy E, Mehran M, Seidman E (1995) Caco-2 cells as a model for intestinal lipoprotein synthesis and secretion. FASEB J 9(8):626-635
15. Litman T, Zeuthen T, Skovsgaard T, Stein WD (1997) Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1361(2):169-176. doi: S0925-4439(97)00027-6 [pii]
16. Loo TW, Clarke DM (2000) Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J Biol Chem 275(50):39272-39278. doi: 10.1074/jbc.M007741200 M007741200 [pii]
17. Maitrejean M, Comte G, Barron D, El Kirat K, Conseil G, Di Pietro A (2000) The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 10(2):157-160. doi: S0960-894X(99)00636-8 [pii]
18. Manach C, Williamson G, Morand C, Scalbert A, Remesy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81(1 Suppl):230S-242S. doi: 81/1/230S [pii]
19. Paiva A, Sousa M, Camões A, Nascimento M, Pinto M (2011) Prenylated xanthones: antiproliferative effects and enhancement of the growth inhibitory action of 4-hydroxytamoxifen in estrogen receptor-positive breast cancer cell line. Med Chem Res 1-7. doi: 10.1007/s00044-011-9562-z
20. Palmeira A, Paiva A, Sousa E, Seca H, Almeida GM, Lima RT, Fernandes MX, Pinto M, Vasconcelos MH (2010) Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone. Chem Biol Drug Des 76(1):43-58
21. Palmeira A, Rodrigues F, Sousa E, Pinto M, Vasconcelos MH, Fernandes MX (2011) New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drug Des 78(1):57-72. doi: 10.1111/j.1747-0285.2011.01089.x
22. Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M, Sousa E (2012) Design of dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochem Pharmacol 83:57-68. doi: 10.1016/j.bcp.2011.10.004
23. Pedro M, Cerqueira F, Sousa ME, Nascimento MS, Pinto M (2002) Xanthones as inhibitors of growth of human cancer cell lines and their effects on the proliferation of human lymphocytes in vitro. Bioorg Med Chem 10(12):3725-3730. doi: S0968089602003796 [pii]
24. Pinto MM, Sousa ME, Nascimento MS (2005) Xanthone derivatives: new insights in biological activities. Curr Med Chem 12(21):2517-2538
25. Sankaran B, Bhagat S, Senior AE (1997) Photoaffinity labelling of P-glycoprotein catalytic sites. FEBS Lett 417(1):119-122. doi: S0014-5793(97)01268-4 [pii]
26. Saraiva L, Fresco P, Pinto E, Sousa E, Pinto M, Goncalves J (2002) Synthesis and in vivo modulatory activity of protein kinase C of xanthone derivatives. Bioorg Med Chem 10(10):3219-3227. doi: S0968089602001694 [pii]
27. Saraiva L, Fresco P, Pinto E, Sousa E, Pinto M, Goncalves J (2003a) Inhibition of alpha, betaI, delta, eta, and zeta protein kinase C isoforms by xanthonolignoids. J Enzyme Inhib Med Chem 18(4):357-370
28. Saraiva L, Fresco P, Pinto E, Sousa E, Pinto M, Goncalves J (2003b) Inhibition of protein kinase C by synthetic xanthone derivatives. Bioorg Med Chem 11(7):1215-1225. doi: S0968089602006417 [pii]
29. Serra H, Mendes T, Bronze MR, Simplicio AL (2008) Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem 16(7):4009-4018. doi: 10.1016/j.bmc.2008.01.028 S0968-0896(08)00045-X [pii]
30. Sousa EP, Silva AMS, Pinto MMM, Pedro MM, Cerqueira FAM, Nascimento MSJ (2002) Isomeric kielcorins and dihydroxyxanthones: synthesis, structure elucidation, and inhibitory activities of growth of human cancer cell lines and on the proliferation of human lymphocytes in vitro. Helv Chim Acta 85(9):2862-2876. doi: 10.1002/1522-2675(200209)85:9<2862:aid-hlca2862>3.0. co;2-r
31. Sousa MEl, Afonso CMM, Pinto MMM (2003) Quantitative analysis of kielcorins in biomimetic synthesis by liquid chromatography/UV detection. J Liq Chromatogr Relat Technol 26(1):29-41
32. Sousa E, Paiva A, Nazareth N, Gales L, Damas AM, Nascimento MSJ, Pinto M (2009) Bromoalkoxyxanthones as promising antitumor agents: synthesis, crystal structure and effect on human tumor cell lines. Eur J Med Chem 44(9):3830-3835
33. Tchamo DN, Dijoux-Franca MG, Mariotte AM, Tsamo E, Daskiewicz JB, Bayet C, Barron D, Conseil G, Di Pietro A (2000) Prenylated xanthones as potential P-glycoprotein modulators. Bioorg Med Chem Lett 10(12):1343-1345. doi: S0960-894X(00)00234-1 [pii]
34. Teixeira M, Afonso CMM, Pinto MM, Barbosa CM (2008) Development and validation of an HPLC method for the quantitation of 1,3-dihydroxy-2- methylxanthone in biodegradable nanoparticles. J Chromatogr Sci 46:472-478
35. US Pharmacopoeia 24/National Formulary 19, United States Pharmacopeial Convention (1995), vol p.2149, section 1225. Rockville
36. Wang EJ, Casciano CN, Clement RP, Johnson WW (2000) In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 28(5):522-528
37. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10(3):195-204. doi: S0928-0987(00)00076-2 [pii]
38. Zhou S, Feng X, Kestell P, Baguley BC, Paxton JW (2004) Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. J Chromatogr B Analyt Technol Biomed Life Sci 809(1):87-97. doi: 10.1016/j.jchromb.2004.06.009